PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Phase 2

Completed

• Conditions: Melanoma; Breast Neoplasms; Carcinoma, Renal Cell; Lymphoma, T-Cell; Carcinoma, Non-Small-Cell Lung
• Interventions: Drug: PF-3512676

• Registration Number: NCT00043368
• Lead Sponsor: Pfizer

Brief Summary

This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2002-08-08
• Study First Submitted QC: 2002-08-09
• Study First Posted: 2002-08-12
• Study Start: 2002-09
• Primary Completion: 2007-06
• Study Completion: 2007-06
• Status Verified: 2009-03
• Last Update Submitted: 2009-03-11
• Last Update Posted: 2009-03-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection alone or in combination with other anti-neoplastic treatment for malignancy.

Exclusion Criteria

The patient has received any anti-neoplastic therapy since completing a prior trial with PF-3512676 Injection, or has participated in another clinical trial following participation in a trial with PF-3512676 Injection.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	PF-3512676	Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.

Primary Outcome Measures

Name	Time	Method
Adverse Events and DLTs will be evaluated by the Investigator and summarized.	indeterminate

Secondary Outcome Measures

Name	Time	Method
No formal statistical analysis of this study will be conducted. All clinical data may be summarized and included in data listings.	indeterminate

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇩🇪 Koeln, Germany